CCND1 Amplification Contributes to Immunosuppression and Is Associated With a Poor Prognosis to Immune Checkpoint Inhibitors in Solid Tumors.
Saved in:
| Title: | CCND1 Amplification Contributes to Immunosuppression and Is Associated With a Poor Prognosis to Immune Checkpoint Inhibitors in Solid Tumors. |
|---|---|
| Authors: | Chen Y; Department of Medical Oncology, Fujian Medical University Cancer Hospital & Fujian Cancer Hospital, Fuzhou, China.; Cancer Bio-immunotherapy Center, Fujian Medical University Cancer Hospital & Fujian Cancer Hospital, Fuzhou, China.; Fujian Provincial Key Laboratory of Translational Cancer Medicine, Fuzhou, China., Huang Y; Fujian Medical University Cancer Hospital, Fuzhou, China., Gao X; Geneplus-Beijing, Beijing, China., Li Y; Fujian Medical University Cancer Hospital, Fuzhou, China., Lin J; Department of Medical Oncology, Fujian Medical University Cancer Hospital & Fujian Cancer Hospital, Fuzhou, China.; Cancer Bio-immunotherapy Center, Fujian Medical University Cancer Hospital & Fujian Cancer Hospital, Fuzhou, China.; Fujian Provincial Key Laboratory of Translational Cancer Medicine, Fuzhou, China., Chen L; Department of Medical Oncology, Fujian Medical University Cancer Hospital & Fujian Cancer Hospital, Fuzhou, China.; Cancer Bio-immunotherapy Center, Fujian Medical University Cancer Hospital & Fujian Cancer Hospital, Fuzhou, China.; Fujian Provincial Key Laboratory of Translational Cancer Medicine, Fuzhou, China., Chang L; Geneplus-Beijing, Beijing, China., Chen G; Fujian Provincial Key Laboratory of Translational Cancer Medicine, Fuzhou, China.; Department of Pathology, Fujian Medical University Cancer Hospital & Fujian Cancer Hospital, Fuzhou, China., Guan Y; Geneplus-Beijing, Beijing, China., Pan LK; CCIC Group, Kuok Kim (Macao) Medical Center III, Macao, China.; Hui Xian Medical Center, Macao, China., Xia X; Geneplus-Beijing, Beijing, China., Guo Z; Department of Medical Oncology, Fujian Medical University Cancer Hospital & Fujian Cancer Hospital, Fuzhou, China.; Cancer Bio-immunotherapy Center, Fujian Medical University Cancer Hospital & Fujian Cancer Hospital, Fuzhou, China.; Fujian Provincial Key Laboratory of Translational Cancer Medicine, Fuzhou, China., Pan J; Cancer Bio-immunotherapy Center, Fujian Medical University Cancer Hospital & Fujian Cancer Hospital, Fuzhou, China.; Fujian Provincial Key Laboratory of Translational Cancer Medicine, Fuzhou, China.; Department of Radiation Oncology, Fujian Medical University Cancer Hospital & Fujian Cancer Hospital, Fuzhou, China., Xu Y; Geneplus-Beijing, Beijing, China., Yi X; Geneplus-Beijing, Beijing, China., Chen C; Cancer Bio-immunotherapy Center, Fujian Medical University Cancer Hospital & Fujian Cancer Hospital, Fuzhou, China.; Fujian Provincial Key Laboratory of Translational Cancer Medicine, Fuzhou, China.; Department of Radiation Oncology, Fujian Medical University Cancer Hospital & Fujian Cancer Hospital, Fuzhou, China. |
| Source: | Frontiers in immunology [Front Immunol] 2020 Aug 10; Vol. 11, pp. 1620. Date of Electronic Publication: 2020 Aug 10 (Print Publication: 2020). |
| Publication Type: | Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1664-3224 |
|---|---|
| DOI: | 10.3389/fimmu.2020.01620 |
